Abstract
BackgroundThe value of adjuvant chemotherapy in colorectal cancer is well studied, and guidelines have been established. Little is known about how treatment guidelines are implemented in the everyday clinical setting.MethodsThis national population-based study on nearly 34,000 patients with colorectal cancer evaluates the adherence to present clinical guidelines for adjuvant chemotherapy. Virtually all patients with colorectal cancer in Sweden during the years 2007–2012 and data from the Swedish Colorectal Cancer Registry were included.ResultsIn colon cancer stage III, adherence to national guidelines was associated with lower age, presence of multidisciplinary team (MDT) conference, low co-morbidity, and worse N stage. The MDT forum also affected whether or not high-risk stage II colon cancer patients were considered for adjuvant chemotherapy. Rectal cancer patients both in stage II and III were considered for adjuvant chemotherapy less often than colon cancer patients, but the same factors influenced the decision. Adjuvant chemotherapy was started later than eight weeks after surgery in 30% of colon cancer patients and in 38% of rectal cancer patients.ConclusionsIn Sweden, the adherence to national guidelines for adjuvant chemotherapy in colon cancer stage III is acceptable in younger and healthier patients. MDT conferences are of major importance and affect whether patients are recommended for adjuvant chemotherapy. Special consideration needs to be given to certain subgroups of patients, particularly older patients and patients with poorly differentiated tumors. There is a need to shorten the waiting time until start of chemotherapy.Electronic supplementary materialThe online version of this article (doi:10.1186/1471-2407-14-948) contains supplementary material, which is available to authorized users.
Highlights
The value of adjuvant chemotherapy in colorectal cancer is well studied, and guidelines have been established
Adjuvant chemotherapy is not recommended for rectal cancer stage II or III
During the six-year period, 33,944 patients were included in the Swedish Colorectal Cancer Registry (SCRCR), of which17,521 were in stage II or III
Summary
The value of adjuvant chemotherapy in colorectal cancer is well studied, and guidelines have been established. In Sweden, almost 6000 patients are diagnosed annually with colorectal cancer (CRC), which is the third most common cancer in the world [1]. While international and national guidelines regarding indications for adjuvant chemotherapy in CRC have been established, few population-based studies have evaluated adherence to practice guidelines. Staging and treatment have evolved in recent decades. Since 2008, the guidelines have recommended that patients younger than 76 years of age with stage III colon cancer should be considered for six months of 5-FU-calciumfolinate or capecitabine alone or in combination with oxaliplatin. High-risk stage II colon cancer may be eligible for treatment, as in stage III. Adjuvant chemotherapy is not recommended for rectal cancer stage II or III
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
